BERLIN, Sept 9 – Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.
Focus on Pacibekitug – A Targeted Therapy
Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation.
- The therapy is being developed as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement.
Strategic Fit for Novartis
With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio.
Deal Structure and Approvals
- The board of directors of both companies have unanimously approved the transaction.
- Under the agreement, Novartis will begin a tender offer to buy all outstanding shares of Tourmaline common stock.
Timeline and Closing
- The deal is expected to close in the fourth quarter of 2025.
- Following completion, Tourmaline will become an indirect, wholly owned subsidiary of Novartis.
